GlassScriptPhysician profile
Kimberly M Green
NPI 1447424197
$9,394.62
in general payments reported to CMS, 2019-2025
43 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,331 · 2020: $686 · 2021: $2,040 · 2022: $244 · 2023: $879 · 2024: $1,941 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505 · Consulting Fee: $1,150 · Gift: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.59 |
| Consulting Fee | $1,150.00 |
| Gift | $439.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $1,983.61 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $1,225.21 | 2024 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $682.78 | 2019-2025 | |
| Incyte Corporation | $585.52 | 2019-2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $583.72 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $498.97 | 2019-2024 | Pomalyst |
| Abiomed | $483.09 | 2024 | Impella |
| Pfizer INC. | $349.52 | 2019-2020 | |
| Celgene Corporation | $312.41 | 2019-2024 | Abecma |
| Merck Sharp & Dohme LLC | $285.41 | 2019-2020 | |
| Genentech USA, INC. | $263.86 | 2019-2020 | |
| Abbvie INC. | $253.16 | 2019-2023 | |
| Kyowa Kirin, INC. | $215.27 | 2019 | |
| Amgen INC. | $206.00 | 2019-2020 | |
| Janssen Biotech, INC. | $158.25 | 2019-2025 | Carvykti |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.